BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $NBIX readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07365462-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:~NBI-1065890 readout (P2) · Neurocrine Biosciences $NBIX
DESCRIPTION:Efficacy\, Safety\, and Tolerability of NBI-1065890 Versus Plac
 ebo in Adults With Tardive Dyskinesia\n\nPrimary completion date: 2027-02 
 (estimated) — month only\, shown on the 1st\nPhase 2 · Neuro · Tardive
  Dyskinesia\nEnrollment: 100 · Sites: 48\n\nPrimary completion = last par
 ticipant's primary-endpoint data collected\; topline results usually follo
 w weeks to months later. Sponsor-reported\, often an estimate. Not investm
 ent advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07365462\nhttps://
 clinicaltrials.gov/study/NCT07365462
URL:https://datacutoff.com/radar.html?nct=NCT07365462
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06786624-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:~NBI-1065845 readout (P3) · Neurocrine Biosciences $NBIX
DESCRIPTION:Study to Assess the Efficacy and Safety of NBI-1065845 as an Ad
 junctive Treatment in Participants With Major Depressive Disorder (MDD)\n\
 nPrimary completion date: 2027-07 (estimated) — month only\, shown on th
 e 1st\nOriginally planned: 2026-11 (+8.0 months)\nPhase 3 · Neuro · Majo
 r Depressive Disorder\nEnrollment: 200 · Sites: 18\n\nPrimary completion 
 = last participant's primary-endpoint data collected\; topline results usu
 ally follow weeks to months later. Sponsor-reported\, often an estimate. N
 ot investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06786624
 \nhttps://clinicaltrials.gov/study/NCT06786624
URL:https://datacutoff.com/radar.html?nct=NCT06786624
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06911112-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:~NBI-1065845 readout (P3) · Neurocrine Biosciences $NBIX
DESCRIPTION:NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of
  NBI-1065845 as an Adjunctive Treatment in Participants With Major Depress
 ive Disorder (MDD)\n\nPrimary completion date: 2027-07 (estimated) — mon
 th only\, shown on the 1st\nPhase 3 · Neuro · Major Depressive Disorder\
 nEnrollment: 200 · Sites: 39\n\nPrimary completion = last participant's p
 rimary-endpoint data collected\; topline results usually follow weeks to m
 onths later. Sponsor-reported\, often an estimate. Not investment advice.\
 n\nhttps://datacutoff.com/radar.html?nct=NCT06911112\nhttps://clinicaltria
 ls.gov/study/NCT06911112
URL:https://datacutoff.com/radar.html?nct=NCT06911112
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06963021-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:~NBI-1065845 readout (P3) · Neurocrine Biosciences $NBIX
DESCRIPTION:NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of
  NBI-1065845 as an Adjunctive Treatment in Participants With Major Depress
 ive Disorder (MDD)\n\nPrimary completion date: 2027-07 (estimated) — mon
 th only\, shown on the 1st\nPhase 3 · Neuro · Major Depressive Disorder\
 nEnrollment: 200 · Sites: 35\n\nPrimary completion = last participant's p
 rimary-endpoint data collected\; topline results usually follow weeks to m
 onths later. Sponsor-reported\, often an estimate. Not investment advice.\
 n\nhttps://datacutoff.com/radar.html?nct=NCT06963021\nhttps://clinicaltria
 ls.gov/study/NCT06963021
URL:https://datacutoff.com/radar.html?nct=NCT06963021
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288333-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:~NBI-1117570 readout (P2) · Neurocrine Biosciences $NBIX
DESCRIPTION:Evaluation of NBI-1117570 in Inpatient Adults With Schizophreni
 a\n\nPrimary completion date: 2027-08 (estimated) — month only\, shown o
 n the 1st\nPhase 2 · Neuro · Schizophrenia\nEnrollment: 120 · Sites: 6\
 n\nPrimary completion = last participant's primary-endpoint data collected
 \; topline results usually follow weeks to months later. Sponsor-reported\
 , often an estimate. Not investment advice.\n\nhttps://datacutoff.com/rada
 r.html?nct=NCT07288333\nhttps://clinicaltrials.gov/study/NCT07288333
URL:https://datacutoff.com/radar.html?nct=NCT07288333
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06963034-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:~NBI-1117568 readout (P3) · Neurocrine Biosciences $NBIX
DESCRIPTION:NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adu
 lts With Schizophrenia\n\nPrimary completion date: 2027-10 (estimated) —
  month only\, shown on the 1st\nPhase 3 · Neuro · Schizophrenia\nEnrollm
 ent: 284 · Sites: 21\n\nPrimary completion = last participant's primary-e
 ndpoint data collected\; topline results usually follow weeks to months la
 ter. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps
 ://datacutoff.com/radar.html?nct=NCT06963034\nhttps://clinicaltrials.gov/s
 tudy/NCT06963034
URL:https://datacutoff.com/radar.html?nct=NCT06963034
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07105098-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:~NBI-1117568 readout (P3) · Neurocrine Biosciences $NBIX
DESCRIPTION:NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adu
 lts With Schizophrenia\n\nPrimary completion date: 2027-11 (estimated) —
  month only\, shown on the 1st\nPhase 3 · Neuro · Schizophrenia\nEnrollm
 ent: 284 · Sites: 20\n\nPrimary completion = last participant's primary-e
 ndpoint data collected\; topline results usually follow weeks to months la
 ter. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps
 ://datacutoff.com/radar.html?nct=NCT07105098\nhttps://clinicaltrials.gov/s
 tudy/NCT07105098
URL:https://datacutoff.com/radar.html?nct=NCT07105098
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
